Effects of APOE‐ε4 allele load on brain morphology in a cohort of middle‐aged healthy individuals with enriched genetic risk for Alzheimer's disease. Issue 7 (28th March 2018)

• Record Type: Journal Article
• Authors: Cacciaglia, Raffaele; Molinuevo, José Luis; Falcón, Carles; Brugulat‐Serrat, Anna; Sánchez‐Benavides, Gonzalo; Gramunt, Nina; Esteller, Manel; Morán, Sebastián; Minguillón, Carolina; Fauria, Karine; Gispert, Juan Domingo
• Is Part Of: Alzheimer's & dementia. Volume 14:Issue 7(2018)
• Page Start: 902
• Page End: 912
• Publication Date: 2018-03-28
• Subjects: Alzheimer's disease -- APOE‐ε4 -- Healthy individuals -- Voxel‐based morphometry -- Gray matter volumes -- Aging; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2018.01.016
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Apolipoprotein E ( APOE )‐ε4 is the major genetic risk factor for Alzheimer's disease. However, the dose‐dependent impact of this allele on brain morphology of healthy individuals remains unclear. Methods: We analyzed gray matter volumes (GMvs) in a sample of 533 healthy middle‐aged individuals with a substantial representation of ε4‐carriers (207 heterozygotes and 65 homozygotes). Results: We found APOE ‐ε4 additive GMv reductions in the right hippocampus, caudate, precentral gyrus, and cerebellar crus. In these regions, the APOE genotype interacted with age, with homozygotes displaying lower GMv after the fifth decade of life. APOE ‐ε4 was also associated to greater GMv in the right thalamus, left occipital gyrus, and right frontal cortex. Discussion: Our data indicate that APOE ‐ε4 exerts additive effects on GMv in regions relevant for Alzheimer's disease pathophysiology already in healthy individuals. These findings elucidate the mechanisms underlying the increased Alzheimer's disease risk in ε4‐carriers, suggesting a dose‐dependent disease vulnerability on the brain structure level.